Embracing Change: How Innovators are Advancing Continuous Biopharma Manufacturing

June 12, 2019 8:00 AM - 10:00 AM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

Building on the realization of continuous manufacturing for commercial small molecule APIs and drug products, the dominos finally are beginning to fall into place for the advancement of integrated processes for biopharmaceutical applications. Regulatory engagement, novel and disruptive process and measurement technologies, and simple economics all are playing key roles in recent progress. This forum, intended for a broad audience of scientists and business leaders across the MassBio community, will explore how each of these change-agents are helping to overcome long-time deterrents and, in doing so, have the potential for improving manufacturing reliability and product quality – thereby reducing risks to patients and other key stakeholders.

Discussion and Key Take-Aways Will Include:

  1. Establishing the business case for continuous biomanufacturing – when and for what applications does it make sense?
  2. Applying single-use technologies, automation, and other innovations to enable success in downstream continuous processing.
  3. Advances in measurement and process analytical technologies to enable process/product understanding in alignment with regulatory guidances.
Forum Bonus: We will have extended networking from 10am-11am so you can meet with Bio-Process Systems Alliance, BioPhorum and NIIMBL organizations to learn how they work with industry to accelerate manufacturing innovation as well as find out about their latest white papers, reports and events.
Managing Director, BDO
Thomas C. Ransohoff, M.S is currently Managing Director at the BioProcess Technology Group at BDO USA, LLP and has over 30 years of experience in the biopharmaceutical industry. Mr. Ransohoff's areas of expertise include development and scale-up of biopharmaceutical processes; separations and purification technologies; cGMP manufacturing; and management of technology-based start-up ventures. Before joining BDO, Mr. Ransohoff held senior level positions at BPTC, TranXenoGen, Dyax, Repligen, and Xoma. He is also a co-founder of both Tarpon Biosystems and BioFlash Partners. He serves on a number of scientific and professional advisory boards and holds a Bachelor's degree from MIT and a Master's degree from the University of California, Berkeley, both in Chemical Engineering.